Search Results for: -5a1us01.html

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER

Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate […]

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER

Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate inCombination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met

ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic cancer. 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being

ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER Read More »